and thoroughly Tafluprost Overview Side Effects Dosage Professional Pregnancy More Breastfeeding Warnings User Reviews Support Group Q & A Pronunciation (TA floo prost) Dosage Forms Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product Solution, Ophthalmic [preservative free]: Zioptan: 0.0015% (30 ea, 90 ea [DSC]) [contains disodium edta, polysorbate 80] Slideshow Easy On The Eye - 8 Tips for Maintaining Good Eyesight Brand Names: U.S. Zioptan Pharmacologic Category Ophthalmic Agent, Antiglaucoma Prostaglandin, Ophthalmic Pharmacology Tafluprost acid is a fluorinated prostaglandin F 2 -alpha analog believed to reduce intraocular pressure by increasing outflow of aqueous humor via the uveoscleral pathway; exact mechanism by which it reduces IOP is unknown. Absorption Through the cornea Metabolism Ester prodrug (tafluprost) is hydrolyzed to the biologically active acid metabolite (tafluprost acid); tafluprost acid metabolized further via fatty acid beta oxidation and phase II conjugation Onset of Action Reduction of intraocular pressure (IOP): 2 to 4 hours; Peak effect: Maximum reduction of IOP: ~12 hours Time to Peak Plasma: ~10 minutes Use: Labeled Indications Elevated intraocular pressure: Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Contraindications There are no contraindications listed in the manufacturer s prescribing information. Dosing: Adult Elevated intraocular pressure: Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP-lowering effect Dosing: Geriatric Refer to adult dosing. Dosing: Renal Impairment There are no dosage adjustments provided in the manufacturer s labeling. Dosing: Hepatic Impairment There are no dosage adjustments provided in the manufacturer s labeling. Administration For ophthalmic use only. Wash hands before use. Avoid touching the tip of the single-use container to eye or other surfaces. Each single-use container has adequate solution to treat both eyes (if applicable); discard immediately after use. If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Storage Store unopened foil pouches refrigerated at 2 C to 8 C (36 F to 46 F). During shipping, may be stored at temperatures up to 40 C (104 F) for no more than 2 days; do not use if mail-order prescriptions arrive after 2 days of the dispensing date. Upon opening the foil pouch, store the single-dose containers at 20 C to 25 C (68 F to 77 F) in the foil pouch; discard unused containers after 30 days. Discard opened single-dose containers immediately after use. Protect from moisture. Drug Interactions Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Monitor therapy Adverse Reactions >10%: Ophthalmic: Conjunctival hyperemia (4% to 20%) 1% to 10%: Central nervous system: Headache (6%) Genitourinary: Urinary tract infection (2%) Infection: Common cold (4%) Ophthalmic: Eye irritation ( 7%), stinging of eyes ( 7%), conjunctivitis (5%), cataract (3%), eye pain (3%), xerophthalmia (3%), blurred vision (2%), hyperpigmentation of eyelashes (2%), increased eyelash length (2%) Respiratory: Cough (3%) 1% (Limited to important or life-threatening): Dyspnea, exacerbation of asthma Warnings/Precautions Concerns related to adverse effects: Ocular effects: May change/increase brown pigmentation of the iris, eyelid, and eyelashes; length, color, thickness, shape, and/or number of eyelashes may also be increased. Pigmentation of the iris is likely to be permanent although iris color change may not be noticeable for months to years; pigmentation of the eyelid and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences and potential injury to eye are not known. Disease-related concerns: Ocular disease: Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Special populations: Pediatric: Use in pediatric patients is not recommended due to possible safety issues of increased pigmentation following long-term use. Monitoring Parameters Intraocular pressure; regularly examine patients who develop increased iris pigmentation Pregnancy Risk Factor C Pregnancy Considerations Adverse events have been observed in animal reproduction studies. Effective contraception during treatment is recommended for women of childbearing potential. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience stinging, itching, blurred vision, eyelash changes, cough, rhinitis, rhinorrhea, sneezing, dry eyes, or headache. Have patient report immediately to prescriber shortness of breath, vision changes, painful urination, difficult urination, severe eye irritation, eye pain, eye discharge, eyelid changes, or eye discoloration (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Pregnancy Warnings Print this page Add to My Med List More about tafluprost ophthalmic Side Effects During Pregnancy or Breastfeeding Dosage Information Support Group En Español 6 Reviews Add your own review/rating Drug class: ophthalmic glaucoma agents Consumer resources Tafluprost ophthalmic Tafluprost Tafluprost Ophthalmic (Advanced Reading) Professional resources Tafluprost (AHFS Monograph) Other brands: Zioptan Related treatment guides Glaucoma, Open Angle Glaucoma/Intraocular Hypertension Intraocular Hypertension Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Tafluprost ophthalmic Rating 6 User Reviews 8.4 /10 6 User Reviews 8.4 Rate it! Drug Class Ophthalmic glaucoma agents Related Drugs ophthalmic glaucoma agents timolol ophthalmic , Lumigan , latanoprost ophthalmic , Travatan , brimonidine ophthalmic , Xalatan Glaucoma, Open Angle timolol ophthalmic , Lumigan , latanoprost ophthalmic , Travatan , brimonidine ophthalmic , Xalatan , epinephrine ophthalmic , Alphagan , More... Glaucoma / Intraocular Hypertension Combigan , Zioptan , Vyzulta , More... Intraocular Hypertension timolol ophthalmic , Lumigan , latanoprost ophthalmic , Travatan , brimonidine ophthalmic , Xalatan , Combigan , Alphagan , More... instructions
superb Tafluprost a terribly
EmoticonEmoticon